APGE
Income statement / Annual
Last year (2024), Apogee Therapeutics, Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2024, Apogee Therapeutics, Inc.'s net income was -$182.15 M.
See Apogee Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$167.87 M
|
$68.42 M
|
$27.79 M
|
| General & Administrative Expenses |
$49.01 M
|
$24.58 M
|
$2.94 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$49.01 M
|
$24.58 M
|
$2.94 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$216.87 M
|
$93.00 M
|
$30.73 M
|
| Cost And Expenses |
$216.87 M
|
$93.00 M
|
$30.73 M
|
| Interest Income |
$34.74 M
|
$9.02 M
|
$92.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$9.15 M
|
| Depreciation & Amortization |
$189.00 K
|
$9.02 M
|
$0.00
|
| EBITDA |
-$216.68 M |
-$74.97 M |
-$39.79 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$34.74 M
|
$9.02 M
|
-$9.06 M
|
| Income Before Tax |
-$182.13 M
|
-$83.99 M
|
-$39.79 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$18.00 K
|
$0.00
|
$0.00
|
| Net Income |
-$182.15 M
|
-$83.99 M
|
-$39.79 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-3.3 |
-1.66 |
-0.79 |
| EPS Diluted |
-3.3 |
-1.66 |
-0.79 |
| Weighted Average Shares Out |
$55.19 M
|
$50.66 M
|
$50.67 M
|
| Weighted Average Shares Out Diluted |
$55.19 M
|
$50.66 M
|
$50.67 M
|
| Link |
|
|
|
